ID   CHLA-122
AC   CVCL_A054
DR   Wikidata; Q54812155
RX   PubMed=11507071;
RX   PubMed=20922763;
RX   PubMed=24792489;
WW   http://www.cccells.org/dl/NB_Data_Sheets/CHLA-122_Cell_Line_Data_Sheet_COGcell_org.pdf
ST   Source(s): COG; PubMed=20922763
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 8,11
ST   D16S539: 9
ST   D18S51: 12,18
ST   D19S433: 13,14
ST   D21S11: 31.2,32.2
ST   D2S1338: 23,25
ST   D3S1358: 15,18
ST   D5S818: 9,12
ST   D7S820: 8
ST   D8S1179: 10,13
ST   FGA: 23,25
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 16,17
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_6590 ! CHLA-136
SX   Female
AG   3Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 21-03-23; Version: 12
//
RX   PubMed=11507071;
RA   Keshelava N., Zuo J.J., Chen P., Waidyaratne S.N., Luna M.C.,
RA   Gomer C.J., Triche T.J., Reynolds C.P.;
RT   "Loss of p53 function confers high-level multidrug resistance in
RT   neuroblastoma cell lines.";
RL   Cancer Res. 61:6185-6193(2001).
//
RX   PubMed=20922763; DOI=10.1002/pbc.22801;
RA   Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J.,
RA   Reynolds C.P.;
RT   "National Cancer Institute pediatric preclinical testing program:
RT   model description for in vitro cytotoxicity testing.";
RL   Pediatr. Blood Cancer 56:239-249(2011).
//
RX   PubMed=24792489; DOI=10.1007/s11060-014-1456-8;
RA   Farooqi A.S., Dagg R.A., Choi L.M.R., Shay J.W., Reynolds C.P.,
RA   Lau L.M.S.;
RT   "Alternative lengthening of telomeres in neuroblastoma cell lines is
RT   associated with a lack of MYCN genomic amplification and with p53
RT   pathway aberrations.";
RL   J. Neurooncol. 119:17-26(2014).
//